Outlook Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +95.8%
EBITDA: —
EBIT: +20.8%
EPS: —
Free cash flow: +26.5%
Operating cash flow: +26.5%

Forward estimates

Revenue: +7224.2%
EBITDA: +123.6%
EPS: +60.8%

Three-year CAGR

Revenue: —
EBITDA: +11.8%
EBIT: +6.5%
Net income: +17.2%
EPS: +55.9%
Free cash flow: +24.7%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.